9th Annual Biomarkers Congress
The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development.
Starling Geneva Hotel & Conference Center (formerly known as the Crowne Plaza Hotel Geneva)
Route François-Peyrot 34 CH-1218 Le Grand Saconnex Geneva • Switzerland +41 22 747 02 02‎
Geneva , Switzerland
http://www.terrapinn.com/2011/european-antibody-congress/speakers-list.stm
Come to the European Antibody Congress 2011 and learn:

    * How to leverage key issues affecting the shifting global antibodies market
    * New advances in understanding structure-function relationships in therapeutic antibodies
    * How to improve efficacy and drugability of monoclonal antibodies
    * Effective identification of monoclonal antibodies against new targets
    * How to improve MAb production scale-up, process transfer and comparability
    * How Antibody Drug Conjugates are on the increase in therapeutic areas
    * How new scaffolds and technologies are being incorporated in the production of antibodies
    * Next generation antibodies, including Biosimilars and Biobetters
    * Novel antibody therapy approaches
    * How Bispecific antibodies are fuelling the biotech engine

The European Antibody Congress 2011 focuses on:

    * Diverse viewpoints from global Pharma and Biotech, on the most important developments in antibody development and discovery today
    * Exploring the novel technologies that are redefining the antibodies market
    * Advances in the assessment and control of the effector functions of therapeutic antibodies
    * Antibody epitopes as a significant factor in therapeutic antibody success
    * Industry benchmarks for antibody-based therapeutics discovery and development
    * Innovative monoclonal antibodies applications – beyond oncology
    * Strategies for efficient ADC target identification and validation
    * Challenges and opportunities in Biosimilars and Biobetter antibodies
    * Developing valuable business relationships during over 10 hours of dedicated networking sessions
    *  Pharmaceutical Manufacturers
    * Biotechs
    * Government / Regulatory Bodies
    * Academia / Research Institutes
    * Contract Service Organisations (CMO and CSO)
    * Equipment Manufacturers & Technology Providers
    * Venture Capitalists
    * Legal Firms
    * Consultants

http://www.terrapinn.com/2011/european-antibody-congress/speakers-list.stm

Schedule of Presentations:

Tuesday, November 29, 2011
08:00:00 Registration and morning coffee
09:00:00 Chairman’s opening remarks Alain Beck
09:05:00 Biosimilar, Biobetters and next generation antibodies Alain Beck
09:30:00 ANTIBODY AND RELATED-PRODUCTS | CHOOSING THE BEST FORMAT
09:35:00 Kinetics on cells-Bridging the gap between traditional biosensor and cell based assay Claudio Rhyner
09:50:00 GLYCO-ENGINEERED BIOBETTER ANTIBODIES
09:55:00 Optimized glyco-engineered IgGs produced in yeast: Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study Dongxing Zha
10:25:00 Biobetter antibodies in oncology in clinical development Steffen Goletz
10:55:00 Speed networking
11:25:00 Morning coffee
11:50:00 IMPROVING EFFICACY AND DRUGABILITY OF mAbS
11:55:00 State-of-the-art analytical methods for mAbs characterization
12:25:00 Biopharmaceutical Characterization – mass spectrometric solutions for challenging analysis
12:45:00 Function-led antibody drug discovery: Solving the target deconvolution bottleneck Jim Freeth
13:05:00 Novartis Predictive tools for stabilization of therapeutic proteins Bernhard Helk
13:35:00 Fully human, better behaved antibody drugs Robert Burns
13:55:00 Networking lunch
14:55:00 Epitope characterization and crystal structure of GA101 provide insight into mechanism of action Christian Klein
15:25:00 Free or total therapeutic monoclonal antibody concentration monitoring Bing Kuang
15:55:00 Effects of molecular properties on antibody pharmacokinetics: recent lessons Saileta Prabhu
16:25:00 MeMo®, a Transgenic Mouse for the Discovery of Innovative Human Antibody Therapeutics Ton Logtenberg
16:45:00 Afternoon refreshments
17:10:00 ANTIBODY EPITOPE MAPPING
17:15:00 Epitope mapping | successes and pitfalls Patrick Schindler
17:45:00 How to obtain desired epitopes by innovative screening and selection strategies
18:15:00 Identification of epitope region and key amino-acid determination using BHP technology as a BioTool Fabrizio Giannotta
18:45:00 Antibody Epitopes | a significant factor in therapeutic antibody success David Lowe
19:15:00 Antibody characterization using unique enzymes in combination with mass spectrometry analysis Sarah Fredriksson
19:30:00 Networking Drinks
Wednesday, November 30, 2011
08:55:00 DISCOVERY OF NOVEL TARGETS FOR MAB THERAPY
09:00:00 Chairman’s opening remarks Paul Parren
09:05:00 Novel Systematic Approach for the Discovery of New Antibody Targets
09:20:00 ANTIBODY SUCCESSES AND ATTRITION RATES
09:25:00 Antibody therapeutics development - state of the art
09:50:00 FROM THE BENCH TO RECENT MARKETING AUTHORISATION
09:55:00 Systems biology approach to the design of optimal antibody-like therapeutic molecules Alexey Lugovskoy
10:25:00 Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
10:55:00 Morning coffee
11:25:00 Novel antibody therapy Approach in Multiple Sclerosis and Schizophrenia Herve Perron
11:50:00 ADDRESSING RESISTANCE – ANTIBODY SYNERGISTIC COMBINATION
11:55:00 Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies Thomas Valerius
12:20:00 PROTEIN MIMICS | ANTIBODY DISCOVERY AGAINST INTRACTABLE TARGETS
12:25:00 CLIPS Technology meets GPCR: A New peptide based strategy for the generation of monoclonal Antibodies against GPCR’s Klaus Schwamborn
12:45:00 Networking lunch
13:35:00 STREAM 2 - MAb PRODUCTION AND SCALE-UP: QUALITY, COMPARABILITY, SAFETY OF ORIGINATOR AND BIOSIMILAR
13:35:00 STREAM 1 | GENERATION AND IDENTIFICATION OF mAbs AGAINST NEW TARGETS
13:40:00 STREAM 1 | Chairman Alexey Lugovskoy
13:40:00 STREAM 2 | Chairman David H Lee
13:45:00 STREAM 1 | The VIVA|SCREEN platform: a high throughput single B lymphocytes screening technology for the rapid discovery and production of fully human antigen-specific monoclonal antibodies Majid Mehtali
13:45:00 New STREAM 2 | Efficient production of antibodies using QMCF Technology, a stable episomal expression platform in mammalian cells Mart Ustav
14:05:00 STREAM 2 | Comparability analysis of protein therapeutics by bottom-up LC-MS with stable isotope-tagged reference standards David H Lee
14:05:00 STREAM 1 | Tetraspanin CD151 as a target for antibody-based cancer immunotherapy Jean-Francois Haeuw
14:35:00 STREAM 2 | Acceptable changes in quality attributes of glycosylated biopharmaceuticals Martin Schiestl
14:35:00 STREAM 1 | Monoclonal antibodies with multi-intervention points: Transgene's MAb to CD115 case study Jean-Yves Bonnefoy
15:05:00 STREAM 2 | Accelerated screening of antibody fragments by cell-free expression
15:05:00 STREAM 1 | Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier Lois Lampson
15:25:00 STREAM 2 | Afternoon refreshments
15:35:00 STREAM 1 | Afternoon refreshments
16:05:00 STREAM 1 | Making Therapeutic Antibodies Fit for Pipeline
16:30:00 STREAM 2 | From Discovery in Academic Setting to Administration in Humans – Developing a Therapeutic Antibody against Hendra and Nipah Viruses Dimiter Dimitrov
16:35:00 STREAM 1 | 515H7 mAb, a new monoclonal antibody which blocks SDF-1/CXCR4 signaling for cancer therapy Christine Klinguer-Hamour
16:45:00 STREAM 2 | SAFETY AND IMMUNOTOXICITY ASSESSMENT OF IMMUNOMODULATORY MONOCLONAL ANTIBODIES
16:50:00 STREAM 2 | Investigating the binding of IgE anti-gal-1.3 alpha-gal antibodies from allergic patients to a panel of therapeutic antibodies Jeroen Lammerts van Bueren,
17:05:00 STREAM 1 | Novel Development in immunotherapy and prophylaxis against influenza A Groups I and II Robert Friesen
17:20:00 STREAM 2 | Human immunoglobulin allotypes: Possible implications for immunogenicity Roy Jefferis,
17:25:00 STREAM 1 | Applying Tag-lite® to therapeutic antibody screening and characterization: A review of recent findings Stephane Martinez
17:45:00 STREAM 1 | Human monoclonal antibodies as adjunct therapies in infectious disease Michael Rudolf
17:50:00 STREAM 2 | Panel session: Definition of antibody critical quality attributes Roy Jefferis,, David H Lee, Martin Schiestl
18:05:00 STREAM 1 | Close of Congress Day 2 followed by Networking Drinks
18:20:00 STREAM 2 | Close of Congress Day 2 followed by Networking Drinks
Thursday, December 1, 2011
08:55:00 WHAT’S FUELING THE BIOTECH ENGINE? ANTIBODY PHARMACO-ECONOMICS
09:00:00 Chairman’s opening remarks Clive Wood
09:00:00 ANTIBODY-DRUG CONJUGATES: TECHNOLOGICAL AND CLINICAL UPDATE
09:05:00 Pre-clinical and clinical ADC programs Hans-Peter Gerber
09:35:00 Bispecific digoxigenin-binding antibodies for targeted payload delivery Ulrich Brinkmann
10:05:00 Strategies for efficient ADC Target Discovery and Lead Selection
10:35:00 Development of advanced antibody-based therapeutics in oncology Bob Lutz
11:05:00 Morning coffee
11:35:00 Linker-Drug Technology based on novel Linker- and Drug chemistries yields Highly Stable and Highly Efficacious ADCs Vincent de Groot
12:00:00 BESIDE ANTIBODIES: DOMAIN ANTIBODIES AND NEW SCAFFOLDS
12:05:00 Single domain antibody development: incorporating Nanobodies® into clinical programmes Hilde Revets
12:35:00 Update on Dyax pipeline and technology and Ecalantide approval success story Andrew Nixon
13:05:00 Path to clinical development of Anticalins and other new scaffolds Laurent Audoly
13:35:00 Networking lunch
14:30:00 BI-SPECIFIC AND RECOMBINANT OLIGOCLONAL ANTIBODIES
14:35:00 Bispecific antibodies: CrossMAb and others Christian Klein
15:05:00 Development of dual-variable domain (DVD) - Ig technology platform: Pre-clinical evaluation of multiple distinct DVD - Ig molecules Tariq Ghayur
15:35:00 Evolution of Potent and Stable Placental-Growth-Factor-1-Targeting CovX-Bodies from Phage Display Peptide Discovery Kristen Bower
16:05:00 Panel session Day 3: Bispecific antibodies and antibody-drug-conjugates Tariq Ghayur, Ulrich Brinkmann, Hans-Peter Gerber
16:35:00 Close of Congress and refreshments
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.